×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| Syngene International Limited | 8159.0 | 740.0 | 7993.0 | 1.83 | 26,171 | 51.6 |
| WOCKHARDT LTD. | 4380.0 | 690.0 | 4130.0 | 4.25 | 23756 | 466.0 |
| PFIZER LTD. | 6702.2 | 1917.5 | 6030.5 | 41.91 | 23444 | 153.0 |
Syngene International Limited, with Security Code 539268, is a leading player in the Healthcare Research- Analytics & Technology industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 994.4 | 715.8 | 830.7 | 791.9 | 864.7 | 726.5 | 821.3 | 877.1 | 948.4 | 799.3 |
| Expenses | 678.0 | 552.4 | 614.1 | 592.4 | 565.4 | 578.3 | 612.7 | 626.3 | 638.4 | 631.2 |
| Operating Profit | 316.4 | 163.4 | 216.6 | 199.5 | 299.3 | 148.2 | 208.6 | 250.8 | 310.0 | 168.1 |
| OPM % | 31.82% | 22.83% | 26.07% | 25.19% | 34.61% | 20.4% | 25.4% | 28.59% | 32.69% | 21.03% |
| Other Income | 22.8 | 22.9 | 13.6 | 25.1 | 15.3 | 49.7 | 16.4 | 18.0 | 18.4 | 16.6 |
| Interest | 10.4 | 6.1 | 8.6 | 6.3 | 8.5 | 7.4 | 7.0 | 6.7 | 10.1 | 5.9 |
| Depreciation | 88.1 | 88.7 | 90.9 | 93.6 | 95.7 | 91.7 | 93.7 | 92.3 | 89.6 | 94.6 |
| Profit before tax | 240.7 | 91.5 | 138.1 | 128.4 | 210.4 | 66.8 | 124.3 | 169.8 | 228.7 | 84.2 |
| Tax % | -21.5% | -17.7% | -22.3% | -20% | -9.8% | -25.2% | 22.3% | 27.5% | -23.7% | 12.1% |
| Net Profit | 189.0 | 75.3 | 101.6 | 99.8 | 189.8 | 73.9 | 96.6 | 123.1 | 174.4 | 74.0 |
| EPS in Rs | 4.68 | 1.87 | 2.53 | 2.48 | 4.72 | 1.84 | 2.41 | 3.06 | 0 | 1.83 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 785.9 | 994.4 | 808.1 | 910.1 | 853.5 | 916.9 | 789.7 | 891.0 | 943.7 | 1,018.0 |
| Expenses | 554.9 | 680.3 | 596.2 | 656.0 | 622.0 | 600.0 | 619.9 | 646.2 | 660.1 | 674.4 |
| Operating Profit | 231.0 | 314.1 | 211.9 | 254.1 | 231.5 | 316.9 | 169.8 | 244.8 | 283.6 | 343.6 |
| OPM % | 29.39% | 31.59% | 26.22% | 27.92% | 27.12% | 34.56% | 21.5% | 27.47% | 30.05% | 33.75% |
| Other Income | 17.2 | 22.8 | 23.6 | 14.2 | 25.6 | 16.1 | 50.1 | 16.5 | 18.3 | 18.9 |
| Interest | 13.7 | 10.4 | 10.5 | 13.0 | 10.8 | 12.9 | 11.7 | 13.1 | 12.4 | 15.9 |
| Depreciation | 94.6 | 95.6 | 102.1 | 104.6 | 108.1 | 111.1 | 106.9 | 110.9 | 108.7 | 106.1 |
| Profit before tax | 139.9 | 230.9 | 122.9 | 158.1 | 141.9 | 209.0 | 69.3 | 137.3 | 180.8 | 240.5 |
| Tax % | -21.6% | -22.6% | -24% | -22.7% | -19.3% | -9.8% | 25.3% | -22.7% | -27.5% | -23.8% |
| Net Profit | 109.7 | 178.7 | 93.4 | 116.5 | 111.5 | 188.6 | 75.7 | 106.1 | 131.1 | 183.3 |
| EPS in Rs | 2.71 | 4.43 | 2.32 | 2.9 | 2.77 | 4.69 | 1.88 | 2.64 | 3.26 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 11% |
| 3 Years: | 9% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 4% |
| 3 Years: | 2% |
| TTM: | -5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 12% |
| 3 Years: | 5% |
| 1 Year: | -7% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 13% |
| 3 Years: | 12% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 6% |
| 3 Years: | 4% |
| TTM: | -9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 12% |
| 3 Years: | 5% |
| 1 Year: | -7% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|